Background And Purpose: Primary rectal squamous cell carcinoma (SCC) is an uncommon disease. Early reports stated that surgery is the most effective treatment. However, recent publications suggest conservative strategy with chemoradiation provides satisfactory results.
Patients And Methods: We have retrospectively studied the medical charts of 23 patients treated for a rectal SCC in two teaching hospitals in France between 1992 and 2013. Twenty-one patients received an exclusive chemoradiotherapy (CRT) and two a pre-operative CRT followed by a planned surgery. Patients received pelvic irradiation with a dose ranging from 36-45 Gy followed by a boost of 15-23 Gy. Twenty-two patients received a concurrent chemotherapy.
Results: After CRT, the rate of clinical complete response was 83%. With a median follow-up of 85 months, 5-year overall survival rate was 86%. Five patients presented with a relapse. The 5-year disease-free survival rate was 81%. The 5-year colostomy-free survival rate was 65%. Three patients (13%) presented with grade III-IV late rectal toxicity.
Conclusions: Although retrospective, this is the largest cohort of patients treated with CRT for a rectal SCC. Exclusive CRT could result in high local control rate and prolonged survival in rectal SCC patients with a high rate of organ preservation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejca.2016.02.005 | DOI Listing |
Surg Oncol Clin N Am
January 2025
Colon & Rectal Surgery, Department of Surgery, University of Michigan, 1500 East Medical Center Drive, 2900 Taubman Center, Ann Arbor, MI 48109, USA. Electronic address:
Anal cancer, though rare, is witnessing an annual increase in incidence, predominantly of squamous cell carcinoma (SCC). Prevention strategies revolve around reducing risk factors such as human papillomavirus (HPV) infection, human immunodeficiency virus/acquired immunodeficiency syndrome, immunosuppression, smoking, and high-risk sexual practices, while advocating for HPV vaccination. The Anal Cancer-HSIL Outcomes Research trial validates treating anal high-grade squamous intraepithelial lesion to curb SCC development.
View Article and Find Full Text PDFClin Radiol
October 2024
Imperial College London (Department of Surgery and Cancer), Department of Surgery and Cancer, Imperial College, Room BN1/2, B Block 1st Floor, Hammersmith Campus, Imperial College, Du Cane Road, W12 0HS, UK. Electronic address:
Aim: This study aimed to determine the prognostic significance of length of tumour (mrT stage) and depth of extramural spread (mrEMS) in anal squamous cell cancer (SCC) treated by chemoradiation with curative intent. Locally advanced anal SCC (T3-4 N+) have poorer prognosis, but it is unknown whether the lateral spread of the tumour (extramural spread beyond the bowel wall) also confers poor prognosis in anal SCC, as it does for rectal cancer. T stage and mrEMS can be readily assessed by pelvic magnetic resonance imaging (MRI) routinely undertaken to stage anal SCC.
View Article and Find Full Text PDFAnimals (Basel)
October 2024
Ruminant Research Group (G2R), Department of Animal and Food Sciences, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
This study evaluated short-term immune responses of dairy ewes supplemented with barley β-glucan (BG) following an intramammary lipopolysaccharide (LPS) challenge. In the adaptation period, 36 ewes were fed an alfalfa hay diet ad libitum and barley grain cv. Hispanic (3.
View Article and Find Full Text PDFJ Surg Case Rep
August 2024
Department of Colon and Rectal Surgery, Hospital Médica Sur, Mexico City, Mexico.
Anal cancer is uncommon, comprising 2.2% of gastrointestinal cancers. Squamous cell carcinoma (SCC) is the most common; while perianal basal cell carcinoma (BCC) is rare, representing only 0.
View Article and Find Full Text PDFJ Natl Cancer Inst
August 2024
Division of Colon & Rectal Surgery, Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
Purpose: To assess the effectiveness and harms of initial treatment strategies for stages I-III anal squamous cell cancer (SCC).
Methods: We searched Medline®, Embase®, and CENTRAL®, between January 1, 2000- March 2024, for randomized controlled trials and nonrandomized studies of interventions comparing initial treatment strategies. Individual study risk of bias (RoB) and overall strength of evidence (SOE) were evaluated for a prespecified outcome list using standardized methods.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!